LOXO-RET-18037 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

NCT03906331

A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Loxo Oncology

LOXO-292 is an oral investigational drug that may treat your cancer. LOXO-292 is a tyrosine kinase inhibitor designed to inhibit a protein called RET. As a result, LOXO-292 might be more effective in tumors with abnormalities in the RET gene. Non-small cell lung and thyroid cancer are most commonly associated with RET gene abnormalities though other tumor types may have them too.